Beyond Air
XAIR
Market cap $24.4M

0.3410 USD

+0.0105

3.18%

At close Oct 11, 4:00 PM EDT

After hours

0.3240

-0.0170

4.99%

1 day

3.18%

5 days

-21.43%

1 month

-11.86%

3 months

-42.98%

6 months

-77.27%

Year to date

-82.69%

1 year

-84.50%

5 years

-92.41%

About: Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Employees: 107

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

238% more call options, than puts

Call options by funds: $54K | Put options by funds: $16K

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

2% less funds holding

Funds holding: 66 [Q1] → 65 (-1) [Q2]

21.09% less ownership

Funds ownership: 47.39% [Q1] → 26.3% (-21.09%) [Q2]

47% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 19

78% less capital invested

Capital invested by funds: $29.7M [Q1] → $6.49M (-$23.2M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$1

193%

upside

Avg. target

$1.50

340%

upside

High target

$2

487%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Roth MKM Jason White 0% 1-year accuracy 0 / 1 met price target	487%upside $2	Buy Reinstated	16 Aug 2024
Piper Sandler Jason Bednar 55% 1-year accuracy 23 / 42 met price target	193%upside $1	Overweight Maintained	7 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about XAIR published over the past 30 days

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced being selected to present two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024, which is scheduled to be held November 6–10 at the George R. Brown Convention Center in Houston, Texas. Abstracts are scheduled to be released to SITC registrants on November 5, 2024, 9:00 AM U.S. ET.

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

Revolutionary inhaled nitric oxide technology set to reach broader healthcare systems Revolutionary inhaled nitric oxide technology set to reach broader healthcare systems

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, is proud to announce the deployment of its groundbreaking LungFit® PH system to the U.S. Naval Hospital Guam. This partnership, made possible through collaboration with TrillaMed, marks a significant advancement in the neonatal critical care unit, offering enhanced care for newborns in need of respiratory support.

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group –

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 – – Avenue Capital, current insiders, and select group of healthcare-focused investment funds participated in the equity offering – GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors, as well as Company insiders.

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York on October 9th.

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Zacks Investment Research

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Misses Revenue Estimates

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.45 per share a year ago.

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Misses Revenue Estimates

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

GARDEN CITY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”), today announced the publication of its scientific article, “A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomized clinical study” in Scientific Reports, an online peer-reviewed journal from the publishers of Nature. The article is freely available online at https://www.nature.com/articles/s41598-024-68055-w.

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

Zacks Investment Research

New Strong Buy Stocks for July 25th

BSVN, OKTA, SVM, SFIX and XAIR have been added to the Zacks Rank #1 (Strong Buy) List on July 25, 2024.

New Strong Buy Stocks for July 25th

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

GARDEN CITY, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that it will report financial results for its first fiscal quarter 2025 ended June 30, 2024 on Tuesday, August 6, 2024 after the market closes.

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

See News Rankings

Charts implemented using Lightweight Charts™